Year 2022 (56)

Edition nr. 2

Finerenone for type 2 diabetes and chronic kidney disease

Treatment for patients with type 2 diabetes mellitus and chronic kidney or cardiovascular disease has to focus on blocking the renin-angiotensin-aldosterone system (RAAS). In specific cases, the (off-label) addition of a competitive aldosterone r ...

In short Read article

Ondansetron for children with gastro-enteritis

Ondansetron is a serotonin receptor antagonist which has been authorised for use as an anti-emetic in the context of chemotherapy (from an age of 6 months) and radiotherapy (in adults). It has also been authorised for the prevention and treatment ...

In short Read article

Direct-acting antiviral agents for chronic hepatitis C

Recent years have seen major progress in the treatment of chronic hepatitis C. New direct-acting antiviral agents (DAAs) have become available in the Netherlands from the end of 2014. Combinations of DAAs against hepatitis C, some of which are ac ...

In short Read article